Bangalore:Bioconhas announced theappointmentof Rajesh Umakant Shanoy as the Company Secretary and Compliance Officer of the company. This follows the cessation of Ekta Agarwal as the Interim Company Secretary and Compliance Officer of the Company with effect from close of business hours of September 09, 2025. "We would like to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held on September 09, 2025 has approved appointment of Rajesh Umakant Shanoy (ICSI Membership No.: ACS 16328), as the Company Secretary and Compliance Officer (being Key Managerial Personnel) of the Company with effect from September 10, 2025 pursuant to the provisions of Regulation 6 of SEBI Listing Regulations and Section 203 of the Companies Act, 2013," Biocon stated in a BSE filing. Biocon Limited, publicly listed in 2004, is a global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. Read also:Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!